Exposure-Based Treatment for Undifferentiated Somatic Symptom Disorder

Not Applicable

Completed

• Conditions: Somatic Symptom Disorder
• Interventions: Behavioral: Exposure

• Registration Number: NCT04511286
• Lead Sponsor: Karolinska Institutet

Brief Summary

This study investigates the feasibility of a general exposure-based treatment protocol that is intended to work for a large variety of patient groups with a clinically significant preoccupation with physical symptoms. This is a prospective single-group study based at Karolinska Institutet, Stockholm, Sweden, where 40 adults with DSM-5 somatic symptom disorder are enrolled in 8 weeks of therapist-guided exposure-based treatment via the Internet. Exposure is based on general principles but tailored to suit the needs of each patient. Outcomes include patient-reported credibility and expectancy, adherence to the treatment protocol, client satisfaction, and negative events. Within-group effects will also be quantified and discussed in relation to the existing literature.

Detailed Description

Background:

A substantial portion of patients in routine care suffer from a recurrent preoccupation with physical symptoms, which often leads to substantial suffering and impairment. Exposure-based treatment - where the patient systematically seeks out that which gives rise to unwanted sensations, cognitions, or behavior - has been found to lead to beneficial effects in several types of symptom preoccupation. Yet, this form of treatment is rarely offered in routine care. This may be partially because existing treatment protocols have been developed for specific symptom clusters (e.g., functional somatic syndromes such as irritable bowel syndrome and fibromyalgia) or specific unwanted responses to symptoms (e.g., the fear of having a severe illness), and that many clinics do not have the resources to offer all these specialized protocols in parallel. An alternative approach could be to base exposure treatment on a more general protocol that may be tailored to suit a larger variety of patient groups who suffer from a recurrent preoccupation with physical symptoms. However, it is yet unclear if the use of such a general treatment protocol for symptom preoccupation would be feasible, for example in terms of patient-reported credibility, adherence, identification with the rationale, and general client satisfaction.

Aim:

To investigate the feasibility of delivering exposure-based treatment using a general protocol for clinically significant symptom preoccupation, without selecting patients based on any specific symptom cluster (such as a functional somatic syndrome) or specific unwanted response to physical symptoms (such as a frequent fear of illness).

Design:

This is a prospective single-group feasibility study based at Karolinska Institutet, Stockholm, Sweden, where 40 adults with somatic symptom disorder according to the Diagnostic and statistical manual of mental disorders 5 (DSM-5) are enrolled in 8 weeks of therapist-guided exposure-based treatment that is delivered via the Internet. Various aspects of feasibility are assessed; most notably: patient-reported credibility and expectancy, adherence to the treatment protocol, client satisfaction, and negative events. Within-group effects are also quantified.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2020-07-18
• Study First Submitted QC: 2020-08-10
• Study First Posted: 2020-08-13
• Study Start: 2020-09-11
• Primary Completion: 2021-02-24
• Study Completion: 2021-02-24
• Status Verified: 2021-07
• Last Update Submitted: 2021-07-19
• Last Update Posted: 2021-07-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 33

Inclusion Criteria

• DSM-5 somatic symptom disorder
• Interest in 8-week intensive psychological treatment to reduce distress and the impact of physical symptoms
• At least 18 years old
• Living in Sweden
• Fluent in Swedish
• Complete pre-treatment assessment

Read More

Exclusion Criteria

• Preoccupation with physical symptoms better explained by another psychiatric condition such as illness anxiety disorder, panic disorder, or obsessive-compulsive disorder
• Severe psychiatric condition, such as bipolar disorder, suicidal ideation, or psychosis
• Medical risks associated with participating in exposure-based treatment, or somatic condition - or treatment for somatic condition - that is an obstacle to participating in exposure-based treatment
• Non-stable continuous pharmacotherapy (dosage changed during the past 4 weeks) and the drug is likely to affect outcome measures (primarily: antidepressants, anticonvulsants, benzodiazepines, nonbenzodiazepines, opioids)
• Alcohol or substance use that is a clear obstacle to therapy
• Planned absence for more than 1 week of the treatment period

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Internet-delivered exposure-based treatment	Exposure	Eight weeks of therapist-guided exposure-based treatment delivered via the Internet.

Primary Outcome Measures

Name	Time	Method
Feasibility 2: credibility/expectancy based on the Credibility/Expectancy scale	Week 3 of treatment	Theoretical range: 0-50, higher score indicates higher credibility/expectancy
Feasibility 4: patient-reported adequacy of rationale as assessed using a questionnaire developed specifically for this purpose (theoretical range: 0-10)	Post-treatment assessment (immediately after treatment, completed within 45 days)	Was originally intended to be administered at week 3, but was administered post-treatment due to an administrative error
Feasibility 7a: adverse events measured using free-text items, primarily reported as the total number of reported events	Post-treatment assessment (immediately after treatment, completed within 45 days)
Feasibility 7b: adverse events measured using the 20-item Negative Effects Questionnaire (NEQ-20)	Post-treatment assessment (immediately after treatment, completed within 45 days)	Theoretical range: 0-80, higher score indicates more severe adverse events
Feasibility 1: distribution of physical symptoms	Pre-treatment assessment (within 2 weeks before treatment)	Primarily according to the Patient Health Questionnaire-15 (PHQ-15, theoretical range: 0-30, higher score indicates more distressing physical symptoms)
Feasibility 3: adherence to the protocol in terms of at least 60% completed modules and at least 50% of participants completing at least 2 exposure exercises	Post-treatment assessment (immediately after treatment, completed within 45 days)
Feasibility 5: adequacy of the measurement strategy in terms of less than 30% missing data at post-treatment, and at least 75% finding the measurement strategy acceptable	Post-treatment assessment (immediately after treatment, completed within 45 days)
Feasibility 6: satisfaction with treatment as indicated by a mean Client Satisfaction Questionnaire (CSQ-8) score of at least 22	Post-treatment assessment (immediately after treatment, completed within 45 days)	Theoretical range: 8-32, higher score indicates higher satisfaction. This sum score is based on 8 items, each scored 1-4. The original preregistered range of 7-28 was an erratum.

Secondary Outcome Measures

Name	Time	Method
Somatic Symptom Disorder-B Criteria Scale (SSD-12)	Screening, pre-treatment assessment (within 2 weeks before treatment), weekly during treatment, Post-treatment assessment (immediately after treatment, completed within 45 days), 3 months after treatment	Theoretical range: 0-48, higher score indicates higher degree of preoccupation with symptoms
Alcohol Use Disorders Identification Test (AUDIT)	Screening only	Theoretical range: 0-40, higher score indicates more problematic alcohol use
Symptom Preoccupation Scale (preliminary scale)	Screening, pre-treatment assessment (within 2 weeks before treatment), weekly during treatment, Post-treatment assessment (immediately after treatment, completed within 45 days), 3 months after treatment	Under development, higher score indicates higher degree of preoccupation with symptoms
Patient Health Questionnaire (PHQ-9)	Screening, pre-treatment assessment (within 2 weeks before treatment), weekly during treatments (suicidality), post-treatment assesment (immediately after treatment, completed within 45 days), 3 months after treatment	Theoretical range: 0-27, higher score indicates more symptoms of depression
GAD-7	Pre-treatment assessment (within 2 weeks before treatment), post-treatment assessment Post-treatment assessment (immediately after treatment, completed within 45 days), 3 months after treatment	Theoretical range: 0-21, higher score indicates more general anxiety
Patient Health Questionnaire-15 (PHQ-15)	Screening, pre-treatment assessment (within 2 weeks before treatment), weekly during treatment, Post-treatment assessment (immediately after treatment, completed within 45 days), 3 months after treatment	Theoretical range: 0-30, higher score indicates more distressing physical symptoms
Drug Use Disorders Identification Test (DUDIT)	Screening only	Theoretical range: 0-44, higher score indicates more problematic substance use
14-item Health Anxiety Inventory (HAI-14)	Screening, pre-treatment assessment (within 2 weeks before treatment), Post-treatment assessment (immediately after treatment, completed within 45 days), 3 months after treatment	Theoretical range: 0-42, higher score indicates more health anxiety
Anxiety Sensitivity Index (ASI)	Screening, pre-treatment assessment (within 2 weeks before treatment), post-treatment assessment Post-treatment assessment (immediately after treatment, completed within 45 days), 3 months after treatment	Theoretical range: 0-64, higher score indicates more anxiety sensitivity
12-item WHO Disability Assessment Schedule 2.0 (WHODAS 2.0)	Screening, pre-treatment assessment (within 2 weeks before treatment), post-treatment assessment (immediately after treatment, completed within 45 days), 3 months after treatment	Theoretical range: 0-100, higher score indicates more disability
Working Alliance Inventory (WAI)	Week 3 of treatment	Theoretical range: 6-42, higher score indicates better relationship with the therapist

Trial Locations

Locations (1)

Karolinska Institutet; 🇸🇪 Stockholm, Sweden